Navigation Links
Researchers seek children for a study of antibiotics for a urinary tract disorder
Date:6/20/2008

Researchers conducting a study to learn if children with a urinary tract disorder known as vesicoureteral reflux (VUR) should be treated with an antibiotic for an extended period of time are seeking to enroll more participants. The study, known as the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) study is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), one of the National Institutes of Health (NIH).

VUR is the abnormal flow of urine from the bladder back up into the tubes that run to the kidneys. These tubes are called ureters. Normally, urine flows down the ureters to the bladder. VUR is the most common functional abnormality of the urinary tract in children. It is found in 30 percent to 50 percent of children with urinary tract infections (UTIs) and is thought to increase the risk of kidney damage when children have recurring UTIs. At least 30 percent of children who have at least one UTI will have a recurrence.

Scar tissue in the kidney, called renal scarring, occurs between 5 percent and 40 percent of the time when a child has a UTI. Scarring may build up with each infection and can lead to progressive kidney failure and the need for renal-replacement therapy, such as dialysis.

About 50 years ago physicians began to prescribe an ongoing regimen of daily antibiotics for children with VUR, based on the belief that treatment would prevent infections and reduce scarring and kidney failure. Unfortunately, the number of children developing kidney failure from VUR has not changed in that time, leading physicians to question the value of the practice and adding to concerns about increasing antibiotic resistance in the general population.

"The RIVUR study has the potential to help us understand how to provide the best care for tens of thousands of children diagnosed every year with this condition," said Marva Moxey-Mims, M.D., director of NIDDK's pediatric nephrology program in the Division of Kidney, Urologic, and Hematologic Diseases. "In addition to finding out if antibiotics reduce the risk of UTIs, we also need to understand the progression of renal scarring and the development of resistance to antibiotics in these children."

The researchers seek to enroll 600 participants. So far, 125 infants and children have joined the study. Participants must be between the ages of 2 months and 6 years and have had their first UTI within the six weeks before their first study visit. With the approval of 20 institutional review boards and an external data safety monitoring board charged with overseeing the safety of children in the trial, each participant receives a daily dose of an antibiotic or a placebo for up to two years. Children who develop recurring fever or other symptoms of infection or scar tissue buildup in the kidney will be switched from the study to routine antibiotic care and referred to a urologist, depending on the number of infections and degree of renal scarring.


'/>"/>

Contact: Arthur Stone
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Researchers confirm benzene-like electron delocalization of important molecule
2. Penn researchers find key developmental pathway activates lung stem cells
3. MIT researchers see alternative to common colorectal cancer drug
4. $10 million gift will retain and recruit world-class researchers to University at Buffalo
5. Researchers ID Traits of Aggressive Prostate Cancer
6. Carnegie Mellon researchers improve assessments of aortic aneurysms
7. Chemical engineering researchers identify biofilms that cause infections
8. MU researchers enhancing motion-capture technology to benefit older adults
9. Researchers Update Risk-of-Death Charts
10. Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients
11. Rutgers researchers show how the brain can protect against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump ... preparing for how his administration could impact the employee benefits industry. James Slotnick, ... are most likely to make it through Congress. His discussion will focus on ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
Breaking Medicine Technology: